A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)

PHASE3CompletedINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

January 23, 2018

Primary Completion Date

July 21, 2019

Study Completion Date

November 20, 2019

Conditions
Hypertriglyceridemia
Interventions
DRUG

CaPre

4 x 1 g capsules administered orally once a day for 26 weeks

DRUG

Placebo

4 x 1 g capsules administered orally once a day for 26 weeks

Trial Locations (69)

15009

Research site, Beaver

24541

Research site, Danville

27408

Research site, Greensboro

28117

Research site, Mooresville

29301

Research site, Spartanburg

30078

Research site, Snellville

30345

Research site, Atlanta

30501

Research site, Gainesville

30518

Research site, Sugar Hill

31406

Research site, Savannah

32256

Research site, Jacksonville

32825

Research site, Orlando

33012

Research site, Hialeah

33026

Research site, Pembroke Pines

33030

Research site, Homestead

33125

Research site, Miami

33126

Research site, Miami

33135

Research site, Miami

33144

Research site, Miami

33155

Research site, Miami

33162

Research site, North Miami Beach

33165

Research site, Miami

33166

Research site, Miami Springs

33173

Research site, Miami

33175

Research site, Kendall

33321

Research site, Tamarac

33401

Research site, West Palm Beach

33409

Research site, West Palm Beach

33449

Research site, Wellington

33461

Research site, Lake Worth

33487

Research site, Boca Raton

33603

Research site, Tampa

33765

Research site, Clearwater

33912

Research site, Fort Myers

35242

Research site, Birmingham

37421

Research site, Chattanooga

38119

Research site, Memphis

38654

Research site, Olive Branch

39202

Research site, Jackson

40213

Research site, Louisville

43302

Research site, Marion

43537

Research site, Maumee

44710

Research site, Canton

46011

Research site, Anderson

49601

Research site, Cadillac

53144

Research site, Kenosha

60031

Research site, Gurnee

63117

Research site, St Louis

68114

Research site, Omaha

70535

Research site, Eunice

72034

Research site, Conway

73069

Research site, Norman

76012

Research site, Arlington

76550

Research site, Lampasas

77084

Research site, Houston

77089

Research site, Houston

78258

Research site, San Antonio

83642

Research site, Meridian

83646

Research site, Meridian

84088

Research site, West Jordan

84107

Research site, Salt Lake City

85712

Research site, Tucson

90717

Research site, Lomita

92020

Research site, El Cajon

92663

Research site, Newport Beach

92780

Research site, Tustin

92844

Research site, Garden Grove

93702

Research site, Fresno

98007

Research site, Bellevue

Sponsors
All Listed Sponsors
lead

Grace Therapeutics Inc.

INDUSTRY